Biogen (NASDAQ:BIIB) Price Target Raised to $225.00 at TD Cowen

Biogen (NASDAQ:BIIB) had its target price hoisted by TD Cowen from $215.00 to $225.00 in a research report released on Thursday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other research firms have also commented on BIIB. Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. HSBC reissued a “reduce” rating and set a $157.00 target price on shares of Biogen in a research note on Monday, July 6th. HC Wainwright reaffirmed a “buy” rating on shares of Biogen in a research report on Thursday, May 14th. Zacks Research upgraded Biogen from a “strong sell” rating to a “hold” rating in a report on Tuesday. Finally, Freedom Capital raised Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Biogen currently has an average rating of “Moderate Buy” and a consensus price target of $223.36.

Biogen Price Performance

BIIB stock opened at $207.93 on Thursday. Biogen has a one year low of $124.56 and a one year high of $219.72. The firm has a 50-day moving average of $201.05 and a two-hundred day moving average of $190.52. The firm has a market capitalization of $30.70 billion, a PE ratio of 36.80 and a beta of 0.16. The company has a current ratio of 1.87, a quick ratio of 2.41 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. During the same period last year, the firm posted $5.47 earnings per share. The firm’s quarterly revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, analysts forecast that Biogen will post 12.38 earnings per share for the current year.

Institutional Investors Weigh In On Biogen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BIIB. Vanguard Group Inc. boosted its stake in shares of Biogen by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock valued at $3,070,514,000 after buying an additional 157,857 shares during the period. Geode Capital Management LLC increased its stake in shares of Biogen by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after acquiring an additional 130,618 shares during the last quarter. Norges Bank acquired a new position in shares of Biogen in the fourth quarter worth $464,408,000. Invesco Ltd. raised its holdings in shares of Biogen by 4.2% during the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after acquiring an additional 98,001 shares in the last quarter. Finally, Morgan Stanley raised its holdings in shares of Biogen by 3.3% during the fourth quarter. Morgan Stanley now owns 2,325,013 shares of the biotechnology company’s stock worth $409,180,000 after acquiring an additional 73,478 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q2 results exceeded expectations: Biogen reported approximately $2.74 billion in revenue, up 3.4% year over year and above the $2.46 billion consensus estimate. Adjusted EPS of $3.60 also topped forecasts near $2.94, supported by stronger rare-disease and newer-product sales. Biogen beats quarterly estimates as newer drugs fuel growth
• Positive Sentiment: Growth portfolio is offsetting legacy weakness: Revenue from Biogen’s Growth Portfolio rose 24% to about $1.06 billion, surpassing its legacy multiple sclerosis portfolio. The Apellis acquisition added sales from SYFOVRE and EMPAVELI, while products including SKYCLARYS and ZURZUVAE contributed to momentum. Biogen’s Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
• Positive Sentiment: Analyst sentiment improved: TD Cowen raised its price target to $225 and assigned a Buy rating, while Morgan Stanley lifted its target to $231 and maintained Equal Weight. Wedbush also raised its target to $215, and Piper Sandler reaffirmed its Buy rating. Analyst target updates
• Neutral Sentiment: 2026 outlook was updated: Biogen expects full-year non-GAAP EPS of $12 to $13 and mid-single-digit revenue growth. The revenue outlook benefits from the newer portfolio, but the EPS range is below the roughly $13.45 analyst consensus, partly reflecting acquisition-related costs. Biogen beats quarterly estimates as newer drugs fuel growth
• Negative Sentiment: Reported profitability deteriorated materially: GAAP net income fell to $97.5 million from $634.8 million a year earlier, while diluted EPS dropped to $0.66 from $4.33. Legacy multiple sclerosis sales also remained under pressure, and Leqembi sales narrowly missed expectations. Biogen profitability compression

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.